Health Technology Assessment: The New Frontier for Gene Therapies in Europe
Author(s)
Moderator: Omar Dabbous, MD, MPH, Novartis Gene Therapies, Inc., Bannockburn, IL, USA
Speakers: Michael Drummond, MCom, DPhil, Centre for Health Economics, University of York, York, YOR, UK; Mondher Toumi, MD, MSc, PhD, Creativ-Ceutical, Paris, France; J.-Matthias Graf Graf von der Schulenburg, PhD, MD, Leibniz University Hannover, Hannover, Germany
Economic evaluation studies may underestimate the value of innovative cell and gene therapies in rare diseases, impacting on Health Technology Assessment (HTA) frameworks, market access and pricing decisions. This symposium will explore the complexities involved in evaluating and valuing gene therapies, to enable patient access to these novel therapies in the European region. Panelists will discuss the affordability challenge posed by novel single-dose treatments, such as gene therapies, compared to chronic therapies historically reimbursed in Europe. They will explore the evolution of the reimbursement landscape for cell and gene therapies in Europe and reflect on the drug value evidence-based challenges for novel therapies such as gene therapy, including how to value benefits beyond quality of life and survival.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Code
208